The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Interim safety analysis of consolidation nivolumab and ipilimumab versus nivolumab alone following concurrent chemoradiation for unresectable stage IIIA/IIIB NSCLC: Big Ten Cancer Research Consortium LUN 16-081.
 
Melissa Yan
No Relationships to Disclose
 
Greg Andrew Durm
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
 
Hirva Mamdani
Consulting or Advisory Role - Tempus
 
Apar Kishor Ganti
Consulting or Advisory Role - Abbvie/Stemcentrx; ARIAD; Pfizer; Takeda
Research Funding - Amgen (Inst); Apexigen (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Janssen Biotech (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Takeda
Travel, Accommodations, Expenses - Genentech/Roche
 
Borys Hrinczenko
Honoraria - bioTheranostics
Consulting or Advisory Role - Bayer
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); EMD Serono (Inst); Endocyte (Inst); ImClone Systems (Inst); Incyte (Inst); Lilly (Inst); Lilly (Inst); Merrimack (Inst); Tragara (Inst); ZIOPHARM Oncology (Inst)
 
Salma K. Jabbour
Consulting or Advisory Role - Merck Sharp & Dohme
Research Funding - Merck Sharp & Dohme (Inst); Nestle health science (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Lawrence Eric Feldman
Stock and Other Ownership Interests - Bristol-Myers Squibb
Research Funding - Biothera (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Soligenix (Inst)
 
Goetz H. Kloecker
Honoraria - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis; Sanofi
Consulting or Advisory Role - Lilly; Novartis
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Novartis
 
Ticiana Leal
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BMS Brazil; Bristol-Myers Squibb; Genentech; Novartis; Takeda; Takeda
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Genentech; Genentech; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Mirati Therapeutics; Novartis; Takeda; Takeda
 
Salah Almokadem
No Relationships to Disclose
 
Jarushka Naidoo
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Roche/Genentech
Research Funding - AstraZeneca (Inst); Calithera Biosciences (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb
 
Naomi Fujioka
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst)
 
Nasser H. Hanna
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck KGaA (Inst)